Biostatistics Department, Singapore Clinical Research Institute, 31 Biopolis Way, Nanos #0201, Singapore 138669; Centre for Quantitative Medicine, Office of Clinical Sciences, Academia, 20 College Road, Singapore Duke-NUS Graduate Medical School, Singapore.
Biostatistics Department, Singapore Clinical Research Institute, 31 Biopolis Way, Nanos #0201, Singapore 138669; Centre for Quantitative Medicine, Office of Clinical Sciences, Academia, 20 College Road, Singapore Duke-NUS Graduate Medical School, Singapore; Department of International Health, School of Medicine, Lääkärinkatu 1, 33014 University of Tampere, Tampere, Finland.
J Clin Epidemiol. 2015 Aug;68(8):895-902. doi: 10.1016/j.jclinepi.2015.02.011. Epub 2015 Mar 3.
To examine the performance of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) global health status/quality of life (QoL) scale and two summary scores to detect changes in the QoL profile over time, according to changes in the individual scales.
Data came from 167 clinical trial patients with unresectable (advanced) hepatocellular carcinoma. The global health status/QoL scale of the questionnaire contained two items: overall health and overall QoL. Nordin and Hinz proposed summary scores for the questionnaire. A mixed-effect model was fitted to estimate trends in scores over time.
Predominantly the individual scale scores declined over time; however, the global health status/QoL score was stable [rate of change = -0.3 per month; 95% confidence interval (CI): -1.2, 0.6]. Nordin's summary score, which gave equal weight to the 15 questionnaire scales, and Hinz's summary score, which gave equal weight to the 30 questionnaire items, showed a statistically significant decline over time, 3.4 (95% CI: -4.5, -2.4) and 4.2 (95% CI: -5.3, -3.0) points per month, respectively.
In contrast to the global health status/QoL scale, the summary scores proposed by Nordin and Hinz detected changes in subjects' QoL profile described by the EORTC QLQ-C30 individual scales.
根据各量表的变化,考察欧洲癌症研究与治疗组织生存质量核心问卷 30 项(EORTC QLQ-C30)整体健康状况/生活质量(QoL)量表和两个综合评分在检测 QoL 特征随时间变化方面的性能。
数据来自 167 名无法切除(晚期)肝细胞癌的临床试验患者。问卷的整体健康状况/QoL 量表包含两个项目:总体健康状况和总体 QoL。Nordin 和 Hinz 提出了问卷的综合评分。采用混合效应模型来估计随时间变化的评分趋势。
主要是个体量表评分随时间下降;然而,整体健康状况/QoL 评分保持稳定[变化率为每月-0.3;95%置信区间(CI):-1.2,0.6]。Nordin 的综合评分对 15 个问卷量表给予同等权重,Hinz 的综合评分对 30 个问卷项目给予同等权重,随时间呈显著下降趋势,每月分别下降 3.4(95%CI:-4.5,-2.4)和 4.2(95%CI:-5.3,-3.0)点。
与整体健康状况/QoL 量表相比,Nordin 和 Hinz 提出的综合评分检测到 EORTC QLQ-C30 个体量表描述的受试者 QoL 特征的变化。